Health Condition 1: C679- Malignant neoplasm of bladder, unspecified Health Condition 2: C61- Malignant neoplasm of prostate
Conditions
Interventions
Intervention1: Computer based optimisation: LymphoTEC guideline to spare lymphocytes
Duration: 5 - 6 weeks during radiotherapy
Control Intervention1: NA: NA
Sponsors
Tata memorial centre
Eligibility
Inclusion criteria
Inclusion criteria: Patients of high risk localized prostate cancer receiving radiotherapy Patients of locally advanced prostate cancer receiving radiotherapy Patients of muscle invasive bladder cancer receiving pelvic radiotherapy Baseline blood lymphocyte count > 800/mm3 Patients must be >= 18 years of age, have the ability to understand, and the willingness to sign a written informed consent document. Patients must have an Eastern Cooperative Oncology Group performance status
Exclusion criteria
Exclusion criteria: Patients receiving prostate only radiotherapy Patients receiving urinary bladder only radiotherapy Patients receiving hypofractionated radiotherapy Baseline lymphocyte count less than 500/mm3 Eastern Cooperative Oncology Group performance status 3 or higher Patients receiving concurrent mitomycin C, cisplatin or other chemotherapeutic agents in bladder cancer HIV positive patients and patients with immunodeficiency states Current smokers Receipt of any other investigational agents or participation in another trial protocol Excessive artifact not allowing proper contouring of target or bone marrow e.g. Hip replacement Inability to lie flat during or tolerate PET/CT, PET/MRI or SABR. Refusal to sign informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of acute lymphopenia (CTCAE v5: Grade 2 or higher)Timepoint: 4 months after radiotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| naTimepoint: na | — |
Countries
India
Contacts
Public ContactPrashanth Giridhar
Department of Radiation Oncology, Tata memorial centre, Varanasi
Outcome results
None listed